Dramatic response of refractory sarcoidosis under ruxolitinib in a patient with associated JAK2-mutated polycythemia.

Competing Interests: Conflict of interest: C. Rotenberg has nothing to disclose. Conflict of interest: V. Besnard has nothing to disclose. Conflict of interest: P-Y. Brillet has nothing to disclose. Conflict of interest: S. Giraudier reports grants from Novartis. Conflict of interest: H. Nunes reports grants and personal fees for consultancy and research from Roche/Genentech and Boehringer Ingelheim, other (for investigator in clinical trials) from Sanofi and Gilead, outside the submitted work. Conflict of interest: D. Valeyre reports personal fees (scientific advisory board membership) from Boehringer Ingelheim and Roche, personal fees for lecturing from AstraZeneca, and personal fees for travel and accommodation from Boehringer Ingelheim and Roche, outside the submitted work.